Company Directory

Natural product-inspired small molecules for sexual and mental health

Kadence Bio is a clinical-stage biopharma company developing small molecule therapeutics for sexual and mental health. Its lead asset KH-001 is an on-demand oral treatment for premature ejaculation, developed from nature-inspired medicinal chemistry based on kanna plant alkaloids and optimised through standard drug development approaches. KH-001 completed Phase 1 safety studies in 2024 and is progressing to Phase 2 trials. A secondary pipeline targets mood disorders through novel neuropsychiatric compounds.

Global biopharma with UK manufacturing, commercial and clinical operations

MSD is a global biopharmaceutical company discovering, developing, manufacturing and marketing medicines and vaccines across oncology, infectious disease, immunology, cardiometabolic disease and animal health. Its UK operations span pharmaceutical manufacturing at Cramlington, Northumberland, which supplies medicines into the Merck global network, alongside commercial and clinical development functions headquartered at Moorgate, London, and an Animal Health division based in Milton Keynes. MSD conducts approximately 150 clinical studies in the UK annually.

Global pharma company in immunology, vaccines, and oncology

GSK is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of medicines and vaccines. Its pipeline and portfolio span respiratory and immunology, oncology, HIV (through its specialist subsidiary ViiV Healthcare), and infectious diseases including vaccines. The company operates major UK sites including its global R&D hub at Stevenage Bioscience Catalyst, manufacturing facilities at Barnard Castle, Ware, and Montrose, and its global headquarters in London's Knowledge Quarter.

Clinical-stage antifungal drug developer targeting invasive fungal infections

F2G is a clinical-stage biopharmaceutical company developing novel antifungal therapies for life-threatening invasive fungal infections. The company discovered the orotomides, a new class of antifungal agents that selectively inhibit fungal dihydroorotate dehydrogenase, a mechanism of action distinct from all approved antifungals. Its lead compound, olorofim, is an oral agent in Phase 3 development for invasive aspergillosis and has received FDA Breakthrough Therapy Designation for multiple indications.

Clinical-stage CNS drug discovery using human brain genomics

Cerevance is a clinical-stage biotechnology company developing small molecule therapeutics for neurodegenerative and psychiatric disorders. The company uses its proprietary platform to profile gene expression in specific neuronal and glial cell types from a collection of over 16,000 annotated human brain tissue samples, identifying novel drug targets. Combined with machine learning analysis, this approach supports a pipeline of CNS therapeutics targeting conditions including Parkinson's disease, Alzheimer's disease and ALS.

Transformative medicines for cystic fibrosis and serious genetic diseases

Vertex Pharmaceuticals is a global biopharmaceutical company with its European R&D headquarters at Milton Park, Oxfordshire, and its international commercial headquarters in London. The Oxford site conducts full-spectrum drug discovery encompassing human genetics, structural biology, and medicinal chemistry, and has been central to Vertex's development of approved therapies for cystic fibrosis. The company's broader pipeline addresses sickle cell disease, beta-thalassaemia, pain, and kidney disease, including gene-edited cell therapies.

Oral and injectable peptide therapies for obesity and cardiometabolic disease

Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders. Its pipeline centres on rationally engineered peptide candidates acting on GLP-1 and amylin receptors, advanced through a proprietary oral absorption technology designed to enable once-weekly dosing. The lead programme is in Phase 2b clinical development, with earlier-stage amylin candidates in preclinical development for monotherapy and combination use.

UK affiliate of global family-owned biopharmaceutical company

Boehringer Ingelheim is a global family-owned biopharmaceutical company founded in 1885. Its Bracknell headquarters houses functions spanning research and development, regulatory affairs, pharmacovigilance, medical affairs, and commercial operations across its human pharma and animal health divisions. It operates across therapeutic areas including respiratory disease, cardiovascular disease, oncology, immunology, and metabolic disorders. It is a member of the ABPI and one of the largest pharmaceutical employers in Berkshire.

Antibody discovery platform identifying therapeutics from resilient individuals

Alchemab Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics for neurodegenerative diseases, oncology, and immunology. Its platform combines deep B cell sequencing and machine learning to identify naturally protective antibodies from individuals resilient to specific diseases. The company's lead programme for amyotrophic lateral sclerosis entered Phase 1 trials following a licensing agreement with Eli Lilly. Alchemab operates from London with research laboratories in Cambridge.

UK commercial base for a rare metabolic disease biotech

Amicus Therapeutics UK is the British subsidiary of Amicus Therapeutics, a US-listed biotechnology company focused on rare metabolic diseases. The company develops enzyme replacement therapies and gene therapies targeting lysosomal storage disorders, with approved medicines for Pompe disease and Fabry disease. The UK office in Marlow serves as the commercial and medical affairs base for Great Britain and Ireland.

Gene therapy company targeting complement-mediated ocular diseases

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies and protein-based therapeutics for diseases driven by dysregulation of the complement immune pathway. A spin-out from the University of Manchester, the company's lead programme CTx001 is an AAV-based gene therapy for geographic atrophy, an advanced form of dry age-related macular degeneration. The company is also developing the Complement Precision Medicine platform for quantification of complement cascade proteins to support diagnosis and patient stratification.

Oral iron deficiency therapy for adults across multiple indications

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on iron deficiency. Its lead product, Accrufer/Feraccru (ferric maltol), is a non-salt-based oral iron therapy approved for the treatment of iron deficiency with or without anaemia in adults across the United States, European Union, United Kingdom, and Switzerland. The product is commercialised directly in the US via a partnership with Viatris, and licensed to Norgine for Europe, the UK, Australia and New Zealand.